| Business Summary | | Corixa
Corporation
is
a
developer
of
immunotherapies
with
a
commitment
to
treating
and
preventing
autoimmune
diseases,
cancer
and
infectious
diseases
by
understanding
and
directing
the
immune
system.
The
Company
has
a
broad
range
of
technology
platforms,
which
enable
both
integrated
vaccine
product
design
and
the
use
of
its
separate
proprietary
technologies
(antigens,
monoclonal
antibodies,
adjuvants,
antigen
delivery
technology
and
tumor
activated
peptide,
or
TAP,
pro-drug
technology)
on
a
standalone,
POWERED
BY
CORIXA
basis.
The
Company
exploits
its
expertise
in
immunology
and
its
proprietary
technology
platforms
to
discover
and
develop
vaccines,
antigen-based
products,
including
therapeutic
antibodies,
novel
adjuvants
and
targeted
oncologics. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Corixa
is
a
research-based
biotechnology
company
committed
to
the
goal
of
treating
and
preventing
diseases
by
understanding
and
directing
the
immune
system.
For
the
six
months
ended
6/30/01,
revenues
rose
67%
to
$29.1
million.
Net
loss
before
acct.
change
and
applicable
to
Common
totalled
$75
million,
up
from
$17.3
million.
Results
reflect
revenue
recognized
from
collaborative
agreements
with
GlaxoSmithKline,
offset
by
increased
payroll
and
personnel
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Steven Gillis, Ph.D., 47 Chairman,
CEO | $440K | Michael Bigham, 43 Vice
Chairman | -- | Michelle Burris, 35 CFO,
Sr. VP | -- | Steven Reed, Ph.D., 50 Exec.
VP, CSO | 266K | Kenneth Grabstein, Ph.D., 50 Exec.
VP of Immunology | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|